SCM
ELVN icon

Silverarc Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Silverarc Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8M Buy
+489,382
New +$20.8M 2.58% 11
2025
Q4 		– Sell
-10,675
Closed -$219K – 82
2025
Q3 		$219K Buy
10,675
+675
+7% +$13.6K 0.03% 78
2025
Q2 		$201K Buy
+10,000
New +$189K 0.04% 62

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Silverarc Capital Management's ELVN Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 489,382 shares worth $24.8M. The stake represents 2.58% of the portfolio and ranks #11 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in ELVN as recently as Q3 2025.

Silverarc Capital Management first reported a position in ELVN in Q2 2025 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Silverarc Capital Management held 489,382 shares of Enliven Therapeutics worth $24.8M as of Q2 2026.
  • Enliven Therapeutics was a new Silverarc Capital Management position in Q2 2026.
  • Enliven Therapeutics made up 2.58% of Silverarc Capital Management's portfolio in Q2 2026, its #11 holding.
  • Silverarc Capital Management first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.